HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
UTMD
Utah Medical Products, Inc.
UTMD's fundamentals are mixed, but it looks expensive: trading at 22x earnings, above its usual 20x. Its downside scenario is about three times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
UTMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Strong |
UTMD's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
UTMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $50.18 | -32% |
| Fair | 20x | $66.55 | -9.6% |
| Current | 22x | $73.63 | — |
| Expensive | 26x | $84.11 | +14% |
Historical ranges are pointers, not guarantees.
UTMD's PE is in its expensive range at 22x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
UTMD Forward outlook
There aren't enough analyst estimates for UTMD to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
UTMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.28 | -12% |
| Q1 2026 | $3.38 | -11% |
| Q4 2025 | $3.48 | -12% |
| Q3 2025 | $3.54 | -17% |
| Q2 2025 | $3.74 | -14% |
| Q1 2025 | $3.78 | -16% |
| Q4 2024 | $3.95 | -14% |
| Q3 2024 | $4.27 | -8% |
UTMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over UTMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
UTMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.5M | -14% |
| Q1 2026 | $8.7M | -10% |
| Q4 2025 | $9M | -1.2% |
| Q3 2025 | $9.8M | -1.9% |
| Q2 2025 | $10M | -4.3% |
| Q1 2025 | $9.7M | -14% |
| Q4 2024 | $9.2M | -26% |
| Q3 2024 | $10M | -20% |
UTMD's revenue has slid since its 2022 peak: $9M last quarter, down 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 31% | -1.1 points |
| Q1 2026 | 29% | -3.1 points |
| Q4 2025 | 27% | -5 points |
| Q3 2025 | 27% | -6.8 points |
| Q2 2025 | 32% | -1 points |
| Q1 2025 | 32% | -1.8 points |
| Q4 2024 | 32% | 0 points |
| Q3 2024 | 33% | +1.7 points |
UTMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over UTMD on cash flow, with more consistent year-over-year improvement.
UTMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $1.2M | -56% |
| Q1 2026 | $3M | -30% |
| Q4 2025 | $3.4M | +15% |
| Q3 2025 | $3.9M | +2.2% |
| Q2 2025 | $2.8M | +6.4% |
| Q1 2025 | $4.3M | -19% |
| Q4 2024 | $2.9M | -44% |
| Q3 2024 | $3.8M | -24% |
UTMD's free cash flow has been positive every quarter for seven years: $11M over the past year, down 17% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over UTMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
UTMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -1K shares |
| 1 year | -1.9% | -62K shares |
| 3 years | -13% | -455K shares |
| 5 years | -13% | -471K shares |
| Available history | -15% | -553K shares |
UTMD has 3M diluted shares, down 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $78,000 |
| Q1 2026 | $128,000 |
| Q4 2025 | $994,000 |
| Q3 2025 | $653,000 |
| Q2 2025 | $3.5M |
| Q1 2025 | $3.2M |
| Q4 2024 | $6.7M |
| Q3 2024 | $3.9M |
UTMD spent $2M buying back its own shares over the past year, down 89% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
UTMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -6.9x | Net Cash |
| Q1 2026 | -6.4x | Net Cash |
| Q4 2025 | -6.0x | Net Cash |
| Q3 2025 | -5.7x | Net Cash |
| Q2 2025 | -5.3x | Net Cash |
| Q1 2025 | -5.3x | Net Cash |
| Q4 2024 | -5.1x | Net Cash |
| Q3 2024 | -5.0x | Net Cash |
UTMD has the edge over HIMS on leverage, with a lower net debt burden relative to earnings.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
UTMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.3 | Neutral |
| Stochastic | 45.8 | Neutral |
UTMD's weekly RSI is 56 (neutral) and its Stochastic is 46 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
UTMD PE vs Healthcare Sector
| Metric | UTMD | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 13% below |
| PE % | 68 | 29 | 39 pts above |
UTMD is trading at 22x earnings, a 13% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
UTMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $73.2 | 0.6% above |
| 20 week MA | $71.7 | 2.6% above |
| 50 week MA | $66.9 | 10% above |
| 100 week MA | $62.5 | 18% above |
| 200 week MA | $71.0 | 3.7% above |
UTMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
UTMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.4 | $85.5 | -21% |
| 2021 | $85.5 | $97.9 | +15% |
| 2022 | $97.9 | $93.6 | -4.4% |
| 2023 | $93.6 | $84.2 | -10% |
| 2024 | $84.2 | $61.9 | -27% |
| 2025 | $61.9 | $56.8 | -8.3% |
| 2026 YTD | $56.8 | $73.6 | +30% |
UTMD has the edge over HIMS on returns for 2026, with the stronger performance.